BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 22391220)

  • 1. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
    Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
    Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drugs modulate ATP-Binding cassette transporter-mediated transport of amyloid beta
    Shubbar MH; Penny JI
    Eur J Pharmacol; 2020 May; 874():173009. PubMed ID: 32061744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide.
    Dodacki A; Wortman M; Saubaméa B; Chasseigneaux S; Nicolic S; Prince N; Lochus M; Raveu AL; Declèves X; Scherrmann JM; Patel SB; Bourasset F
    Sci Rep; 2017 Oct; 7(1):13393. PubMed ID: 29042617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amyloid beta on ATP-binding cassette transporter expression and activity in porcine brain microvascular endothelial cells.
    Shubbar MH; Penny JI
    Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2314-2322. PubMed ID: 30048740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1-40) at the blood-brain barrier.
    Akanuma S; Ohtsuki S; Doi Y; Tachikawa M; Ito S; Hori S; Asashima T; Hashimoto T; Yamada K; Ueda K; Iwatsubo T; Terasaki T
    Neurochem Int; 2008 May; 52(6):956-61. PubMed ID: 18201804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells.
    Kania KD; Wijesuriya HC; Hladky SB; Barrand MA
    Brain Res; 2011 Oct; 1418():1-11. PubMed ID: 21920506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood-cerebrospinal fluid barrier in human brain.
    Matsumoto K; Chiba Y; Fujihara R; Kubo H; Sakamoto H; Ueno M
    Histochem Cell Biol; 2015 Dec; 144(6):597-611. PubMed ID: 26449856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.